Bioxyne Limited, a life sciences and consumer health products company, engages in the manufacture and distribution of consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, cannabis pastilles, THC flowers, vapes, oral liquids, nootropic and skin care products, and mushroom complexes. It also develops various functional food products, such as lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products. In addition, the company provides product research and development services, and telemedicine services. Further, it operates BLS Clinics, a telehealth platform; and CanXChange Australia, a machine-learning driven B2B technology platform for sponsors, manufacturers, cultivators, and pharmacies to interact, manage chain of custody, and buy and sell bulk starting materials, APIs, and finished products in a regulated environment. The company offers its products under the Dr Watson, Mirai Solution, and Apothecary CBD brands. It provides its products online, as well as through wholesale and direct sales in Australia, the United States, the United Kingdom, Japan, Czechia, Switzerland, France, and Germany. The company was incorporated in 1998 and is headquartered in Sydney, Australia.